<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34791088</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>A review of Mendelian randomization in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>832</StartPage><EndPage>842</EndPage><MedlinePgn>832-842</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab420</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a relatively common and rapidly progressive neurodegenerative disease that, in the majority of cases, is thought to be determined by a complex gene-environment interaction. Exponential growth in the number of performed genome-wide association studies combined with the advent of Mendelian randomization is opening significant new opportunities to identify environmental exposures that increase or decrease the risk of amyotrophic lateral sclerosis. Each of these discoveries has the potential to shape new therapeutic interventions. However, to do so, rigorous methodological standards must be applied in the performance of Mendelian randomization. We have reviewed Mendelian randomization studies performed in amyotrophic lateral sclerosis to date. We identified 20 Mendelian randomization studies, including evaluation of physical exercise, adiposity, cognitive performance, immune function, blood lipids, sleep behaviours, educational attainment, alcohol consumption, smoking and type 2 diabetes mellitus. We have evaluated each study using gold standard methodology supported by the Mendelian randomization literature and the STROBE-Mendelian randomization checklist. Where discrepancies exist between Mendelian randomization studies, we suggest the underlying reasons. A number of studies conclude that there is a causal link between blood lipids and risk of amyotrophic lateral sclerosis; replication across different datasets and even different populations adds confidence. For other putative risk factors, such as smoking and immune function, Mendelian randomization studies have provided cause for doubt. We highlight the use of positive control analyses in choosing exposure single nucleotide polymorphisms (SNPs) to make up the Mendelian randomization instrument, use of SNP clumping to avoid false positive results due to SNPs in linkage and the importance of multiple testing correction. We discuss the implications of survival bias for study of late age of onset diseases such as amyotrophic lateral sclerosis and make recommendations to mitigate this potentially important confounder. For Mendelian randomization to be useful to the amyotrophic lateral sclerosis field, high methodological standards must be applied to ensure reproducibility. Mendelian randomization is already an impactful tool, but poor-quality studies will lead to incorrect interpretations by a field that includes non-statisticians, wasted resources and missed opportunities.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Julian</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boddy</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Mahjabin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whittaker</LastName><ForeName>Katherine J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moll</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Calum</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0873-8689</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mendelian randomization</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34791088</ArticleId><ArticleId IdType="pmc">PMC9050546</ArticleId><ArticleId IdType="doi">10.1093/brain/awab420</ArticleId><ArticleId IdType="pii">6429272</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Harvey C, Zhang S, et al. . Advances in the genetic classification of amyotrophic lateral sclerosis. Curr Opin Neurol. Published online August 2, 2021; doi:10.1097/WCO.0000000000000986</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000986</ArticleId><ArticleId IdType="pmc">PMC7612116</ArticleId><ArticleId IdType="pubmed">34343141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041728</ArticleId><ArticleId IdType="pubmed">30002074</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith G, Ebrahim S. &#x2018;Mendelian randomization&#x2019;: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi-Shemirani P, Sjaarda J, Gerstein HC, et al. . A Mendelian randomization-based approach to identify early and sensitive diagnostic biomarkers of disease. Clin Chem. 2019;65(3):427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">30337280</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414999</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Hemani G, Smith GD. Invited commentary: Detecting individual and global horizontal pleiotropy in Mendelian randomization&#x2014;A job for the humble heterogeneity statistic? Am J Epidemiol. 2018;187:2681&#x2013;2685. 10.1093/aje/kwy185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy185</ArticleId><ArticleId IdType="pmc">PMC6269239</ArticleId><ArticleId IdType="pubmed">30188969</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Smith GD, Davies NM, et al. . Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 2019;4:186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384151</ArticleId><ArticleId IdType="pubmed">32760811</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Davies NM, Dimou Net al. . STROBE-MR: Guidelines for strengthening the reporting of Mendelian randomization studies. PeerJ Preprints 7:e27857v1. 10.7287/peerj.preprints.27857v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.7287/peerj.preprints.27857v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan&#x2014;A web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966331</ArticleId><ArticleId IdType="pubmed">24711954</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha SK, Jha NK, Kumar D, Ambasta RK, Kumar P. Linking mitochondrial dysfunction, metabolic syndrome and stress signaling in neurodegeneration. Biochim Biophys Acta Mol Basis Dis. 2017;1863(5):1132&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pubmed">27345267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Steyn FJ. The interplay between metabolic homeostasis and neurodegeneration: Insights into the neurometabolic nature of amyotrophic lateral sclerosis. Cell Regen. 2015;4(1):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551561</ArticleId><ArticleId IdType="pubmed">26322226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorte E, Ferrigno L, Leoncini E, Corbo M, Boccia S, Vanacore N. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: A systematic review. Neurosci Biobehav Rev. 2016;66:61&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">27108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. ; International ALS Genomics Consortium. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. 2009. doi:10.1002/9780470743386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470743386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. Ann Statst. 2020;48(3):1742&#x2013;1769.</Citation></Reference><Reference><Citation>Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4849733</ArticleId><ArticleId IdType="pubmed">27061298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian randomisation via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46:1985&#x2013;1998. 10.1093/ije/dyx102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyx102</ArticleId><ArticleId IdType="pmc">PMC5837715</ArticleId><ArticleId IdType="pubmed">29040600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469799</ArticleId><ArticleId IdType="pubmed">26050253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.e1&#x2013;e202.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: A Mendelian randomization study. Hum Mol Genet. 2019;28(4):688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et al. . Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. bioRxiv. 2021;53:1636&#x2013;1648. 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22(11):1436&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Wang T, Zheng J, Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: New evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17(1):225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo V, Wark PA, Jenab M, et al. . Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: The EPIC cohort. Neurology. 2013;80(9):829&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598455</ArticleId><ArticleId IdType="pubmed">23390184</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tang L, Huang T, Fan D. Life course adiposity and amyotrophic lateral sclerosis: A Mendelian randomization study. Ann Neurol. 2020;87(3):434&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">31916305</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz NA. Life course adiposity and amyotrophic lateral sclerosis: A Mendelian randomization study. Ann Neurol. 2020;88(1):203.</Citation><ArticleIdList><ArticleId IdType="pubmed">32372439</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Glascow N, Barry ADF, et al. . Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine. 2021;68:103397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimentidis YC, Raichlen DA, Bea J, et al. . Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes. 2018;42(6):1161&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195860</ArticleId><ArticleId IdType="pubmed">29899525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhang L, Tang L, Xia K, Huang T, Fan D. Physical activity and amyotrophic lateral sclerosis: A Mendelian randomization study. Neurobiol Aging. 2021;105:374.e1&#x2013;374.e4. 10.1016/j.neurobiolaging.2021.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.04.010</ArticleId><ArticleId IdType="pubmed">34023151</ArticleId></ArticleIdList></Reference><Reference><Citation>Clays E, De Bacquer D, Van Herck K, De Backer G, Kittel F, Holtermann A. Occupational and leisure time physical activity in contrasting relation to ambulatory blood pressure. BMC Public Health. 2012;12:1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551777</ArticleId><ArticleId IdType="pubmed">23164344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin AMG, Shadfar S, Vidal M, Jamali MS, Atkin JD. Motor neuron susceptibility in ALS/FTD. Front Neurosci. 2019;13:532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009;73(20):1693&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788806</ArticleId><ArticleId IdType="pubmed">19917993</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Jones A, Iacoangeli A, et al. . UK case control study of smoking and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3-4):222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261396</ArticleId><ArticleId IdType="pubmed">32301340</ArticleId></ArticleIdList></Reference><Reference><Citation>Schooling CM, Lopez PM, Yang Z, Zhao JV, Au Yeung SL, Huang JV. Use of multivariable Mendelian randomization to address biases due to competing risk before recruitment. Front Genet. 2020;11:610852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845663</ArticleId><ArticleId IdType="pubmed">33519914</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit RAJ, Trompet S, Dekkers OM, Jukema JW, Le Cessie S. Survival bias in Mendelian randomization studies: A threat to causal inference. Epidemiology. 2019;30(6):813&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6784762</ArticleId><ArticleId IdType="pubmed">31373921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Weinberg CR, Chen J. Using family members to augment genetic case-control studies of a life-threatening disease. Stat Med. 2016;35(16):2815&#x2013;2830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4899219</ArticleId><ArticleId IdType="pubmed">26866629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: A Mendelian randomization study. Ann Neurol. 2019;85(4):482&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">30786056</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Wootton RE, Budu-Aggrey A, et al. . Relationship between smoking and ALS: Mendelian randomisation interrogation of causality. J Neurol Neurosurg Psychiatry. 2020;91(12):1312&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">32848012</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Mennini T, Bendotti C, et al. . The heterogeneity of amyotrophic lateral sclerosis: A possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson SC, Mason AM, B&#xe4;ck M, et al. ; Million Veteran Program. Genetic predisposition to smoking in relation to 14 cardiovascular diseases. Eur Heart J. 2020;41(35):3304&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544540</ArticleId><ArticleId IdType="pubmed">32300774</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty KR, Guillot-Sestier M-V, Town T. The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? Brain Res. 2015;1617:155&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362937</ArticleId><ArticleId IdType="pubmed">25218556</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Yang W, Wei Q, Shang H. Causal association of leukocytes count and amyotrophic lateral sclerosis: A Mendelian randomization study. Mol Neurobiol. 2020;57(11):4622&#x2013;4627.</Citation><ArticleIdList><ArticleId IdType="pubmed">32770314</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuckovic D, Bao EL, Akbari P, et al. ; VA Million Veteran Program. The polygenic and monogenic basis of blood traits and diseases. Cell. 2020;182(5):1214&#x2013;1231.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482360</ArticleId><ArticleId IdType="pubmed">32888494</ArticleId></ArticleIdList></Reference><Reference><Citation>Storm CS, Kia DA, Almramhi M, Wood NW. Using Mendelian randomization to understand and develop treatments for neurodegenerative disease. Brain Commun. 2020;2(1):fcaa031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425289</ArticleId><ArticleId IdType="pubmed">32954289</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss KM, Clark AG. Linkage disequilibrium and the mapping of complex human traits. Trends Genet. 2002;18(1):19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, Allen K, Oei F, et al. . Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Roos PM, Larsson SC. Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(10):1913&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">32441415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wang T, Han Z, Liu G. Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases. Neurol Sci. 2020;41(10):2875&#x2013;2882.</Citation><ArticleIdList><ArticleId IdType="pubmed">32328834</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hop PJ, Zwamborn RAJ, Hannon E, et al. . 
Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways. medRxiv. 2021;https://www.medrxiv.org/content/10.1101/2021.03.12.21253115v1.full-text</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.12.21253115v1.full-text</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F, Manera U, Chi&#xf2; A. Alcohol consumption and the risk of amyotrophic lateral sclerosis. In: Neuroscience of Alcohol: Mechanisms and Treatment. Elsevier; 2019:207&#x2013;216.</Citation></Reference><Reference><Citation>Yu X, Wang T, Chen Y, et al. . Alcohol drinking and amyotrophic lateral sclerosis: An instrumental variable causal inference. Ann Neurol. 2020;88(1):195&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">32196748</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2019;48(3):713&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6734942</ArticleId><ArticleId IdType="pubmed">30535378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tang L, Xia K, Huang T, Fan D. Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study. Ann Clin Transl Neurol. 2020;7(9):1642&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480912</ArticleId><ArticleId IdType="pubmed">32810387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, Wedow R, Okbay A, et al. ; Social Science Genetic Association Consortium. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50(8):1112&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393768</ArticleId><ArticleId IdType="pubmed">30038396</ArticleId></ArticleIdList></Reference><Reference><Citation>Border R, Johnson EC, Evans LM, et al. . No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. Am J Psychiatry. 2019;176(5):376&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548317</ArticleId><ArticleId IdType="pubmed">30845820</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, et al. . Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, Hall B, Castelli LM, et al. . Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain. 2019;142(3):586&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391613</ArticleId><ArticleId IdType="pubmed">30698736</ArticleId></ArticleIdList></Reference><Reference><Citation>Group IAS, Others. Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology. 1993;43(12):2466&#x2013;2466.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandan R, Bromberg MB, Forshew D, et al. . A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology. 1996;47(5):1220&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909433</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumi Y, Kaji R. Clinical trials of ultra-high-dose methylcobalamin in ALS. Brain Nerve. 2007;59(10):1141&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">17969354</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: Current perspectives. Nat Sci Sleep. 2019;11:97&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701267</ArticleId><ArticleId IdType="pubmed">31496852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Zhao X, Liu Q, et al. . Study on sleep&#x2013;wake disorders in patients with genetic and non-genetic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;92(1):96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">33087425</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S-Y, Fauman EB, Petersen A-K, et al. ; Multiple Tissue Human Expression Resource (MuTHER) Consortium. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064254</ArticleId><ArticleId IdType="pubmed">24816252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Lv X, Du H, Wu D, Wang M. Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study. Prog Neuropsychopharmacol Biol Psychiatry. 2020;97:109771.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669200</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullell N, C&#xe1;rcel-M&#xe1;rquez J, Gallego-F&#xe1;brega C, et al. . Sleep/wake cycle alterations as a cause of neurodegenerative diseases: A Mendelian randomization study. Neurobiol Aging. 2021;106:320.e1&#x2013;320.e12. 10.1016/j.neurobiolaging.2021.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.05.008</ArticleId><ArticleId IdType="pubmed">34130902</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG.; EPIC-InterAct Consortium. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516908</ArticleId><ArticleId IdType="pubmed">25773750</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: Interpretation and presentation of causal estimates. Eur J Epidemiol. 2018;33(10):947&#x2013;952</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6153517</ArticleId><ArticleId IdType="pubmed">30039250</ArticleId></ArticleIdList></Reference><Reference><Citation>Labrecque JA, Swanson SA. Interpretation and potential biases of Mendelian randomization estimates with time-varying exposures. Am J Epidemiol. 2019;188(1):231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">30239571</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallis HM, Davey Smith G, Munaf&#xf2; MR. Cigarette smoking and personality: Interrogating causality using Mendelian randomisation. Psychol Med. 2019;49(13):2197&#x2013;2205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6747344</ArticleId><ArticleId IdType="pubmed">30355388</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017;28(1):30&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133381</ArticleId><ArticleId IdType="pubmed">27749700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837715</ArticleId><ArticleId IdType="pubmed">29040600</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>